

10/567,660

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Application Number	Not yet assigned
Filing Date	February 8, 2006
First Named Inventor	Suzanne Chamberland et al.
Art Unit	Not yet assigned 1624
Examiner Name	Not yet assigned T. T. TAYLOR

Attorney Docket Number 4810-73194-01

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind code ² (if known)			
TNT ✓	A1	US-2004/0043987	03-04-2004	Neurosearch A/S	
✓	A2	US-2004/0131628 A1	07-08-2004	Bratzler, Robert L. et al.	
✓	A3	US-6,479,499	11-01-2004	National Science Council (TW)	
✓	A4	US-2003-0125344	07-03-2003	Bayer Corporation	
✓	A5	US-2003/0220357	11-27-2003	Bankston, D. et al.	
✓	A6	US-2002161014 A1	10-31-2002	Chanchal, Sadhu et al.	set attached
✓	A7	US-2002/0025968	02-28-2002	Pamkcu, R.; Piazza, G.	Page of Reference
✓	A8	US-6,429,311	08-06-2002	Sepracor Inc.	
✓	A9	US-2001/0018518	08-30-2001	Gao, Yun	
✓	A10	US-6,306,864	10-23-2001	Pfizer, Inc.	
✓	A11	US-6,380,204	10-23-2001	Xerox Corporation	
✓	A12	US-6,184,377 B1	02-06-2001	Sepracor Inc.	
✓	A13	US-5,436,233	07-25-1995	Ono Pharmaceutical Co. Ltd.	
✓	A14	US-5,439,895	08-08-1995	Ono Pharmaceutical Co. Ltd.	
✓	A15	US-3,970,648	07-20-1976	Diamond Shamrock	
✓	A16	US-3,973,021	08-03-1976	Diamond Shamrock	
✓	A17	US-3,974,277	08-20-1976	Diamond Shamrock	
✓	A18	US-3,542,784	11-24-1970	Norwich	
TNT ✓	A19	US-3,324,122	07-06-1967	Norwich	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
TNT ✓	B1	WO 2005/014585 A1	Feb. 17/05	Ulysses Pharmaceuticals Products Inc.		<input type="checkbox"/>
✓	B2	WO 2004/004658 A2	Jan. 15/04	Point Therapeutics, Inc.		<input type="checkbox"/>
✓	B3	WO 2003/091224 A1	Nov 6/03	Nippon Shinyaku Co. Ltd.		<input type="checkbox"/>
TNT ✓	B4	WO 01/81346 A3	Nov. 1/01	ICOS Corp.		<input type="checkbox"/>

Examiner Signature	<i>T. T. Taylor</i>	Date Considered	5/4/07
--------------------	---------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/567,660

		PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.			
Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	Not yet assigned
		Filing Date	February 8, 2006
		First Named Inventor	Suzanne Chamberland et al.
		Art Unit	Not yet assigned 1624
		Examiner Name	Not yet assigned T. TRUONG
Sheet 2	of 3	Attorney Docket Number 4810-73194-01	

Foreign Patent Documents (continued)						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
TNT ✓	B5	WO 9834111 A1	Aug. 6/98	Trega Biosciences Inc. (US)	_____	<input type="checkbox"/>
	B6	WO 9834115 A1	Aug. 6/98	Trega Biosciences Inc. (US)	_____	<input type="checkbox"/>
	B7	DE 2,140,280	Feb. 17/72	Chemische Fabrik von Heyden GmbH	_____	<input type="checkbox"/>
	B8	GB 1,168,430	Oct. 22/69	The Norwich Pharmacal Company	_____	<input type="checkbox"/>
TNT ✓	B9	BE 672504	Mar. 16/66	The Norwich Pharmacal Company	_____	<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.				T ²
TNT ✓	C1	Burch, Homer A., "Nitrofuryl heterocycles, IV.4-Amino-2-(5-nitro-2-furyl) quinazoline derivatives" <i>Journal of Medicinal Chemistry</i> (1966), 9(3), 408-10 ,				<input type="checkbox"/>
	C2	Cohen, Samuel M. et al., "Comparative carcinogenicity of 5-nitrothiophenes and 5-nitrofurans in rats" <i>Journal of the National Cancer Institute</i> (1976), 57(2), 277-82 .				<input type="checkbox"/>
	C3	Desos, Patrice et al. "Structure-Activity Relationships in a Series of 2[1H]-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7 Dichloro-2[1H]-oxoquinoline-3-phosphonic Acid, a New Potent and Selective AMPA/Kainate Antagonist with Neuroprotective Properties" <i>Journal of Medicinal Chemistry</i> (1996) 39(1) 197-206 .				<input type="checkbox"/>
	C4	Gupta, K. "Addressing Antibiotic Resistance" <i>Dis. Mon.</i> (2003) 49(2) 99-110 .				<input type="checkbox"/>
TNT ✓	C5	Hour, Mann-Jen "6-Alkylamino- and 2,3 Dihydro-3'-methoxy-2-phenyl-4-quinazolinones and Related Compounds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization" <i>Journal of Medicinal Chemistry</i> (2000) 43(23) 4479-4487 .				<input type="checkbox"/>

Examiner Signature		Date Considered	5/11/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/567,660

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	Not yet assigned
				Filing Date	February 8, 2006
				First Named Inventor	Suzanna Chamberland et al.
				Art Unit	Not yet assigned 1624
				Examiner Name	Not yet assigned T. TRUMAN
				Attorney Docket Number	4810-73194-01
Sheet 3		of	3		

NON PATENT LITERATURE DOCUMENTS (continued)					
Examiner Initials *	Cite No. ^	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city and /or country where published.			T ²
TNT	C6	Jiang, Jack B. et al. "Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization" <i>Journal of Medicinal Chemistry</i> (1990) 33(6) 1721-28			<input type="checkbox"/>
	C7	Molina, Enrique et al., "Designing Antibacterial Compounds through a Topological Substructural Approach" <i>Journal of Chemical Information and Computer Sciences</i> (2004), 44(2), 515-521			<input type="checkbox"/>
	C8	Moskalenko, N. Yu et al., "4-Amino-2-styrylquinazolines, - a new class of antiprotozoal drugs" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1986), 20(4), 437-46			<input type="checkbox"/>
	C9	Nicolle, L.E. "Urinary Tract Infection: Traditional Pharmacologic Therapies" (2003) 49(2) 111-128			<input type="checkbox"/>
	C10	Ogawa, Nobuo et al. "Synthesis and histamine H2-antagonist activity of 4-quinzolinione derivatives" <i>Chemical & Pharmaceutical Bulletin</i> (1988) 36(8) 2955-67			<input type="checkbox"/>
	C11	Van Natta, J.P. et al., "Determination of untreated whole-milk effects on in vitro antibacterial activity" <i>Applied Microbiology</i> (1970), 19(2), 220-23			<input type="checkbox"/>
	C12	Yakhontov, L.N. et al., "Synthesis and Study of Biological Activity of Substituted 4-Amino-2-Styrylquinazolines" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1975) 9(11) 12-18			<input type="checkbox"/>
	C13	Zhikhareva, G.P. et al., "Synthesis and Anti-Inflammatory Activity of Substituted 2-styryl-4-(δ-diethylamino-α-methylbutylamino)-6-nitro and 2-styryl-4-(δ-diethylamino-α-methylbutylamino)-6-aminoquinazolines" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1980) 14(2), 45-49			<input type="checkbox"/>
TNT	C14	Zhikhareva, G.P. et al., "Synthesis and Antiviral Activity of Substituted 4-(δ-diethylamino-α-methylbutylamino)-2-styrylquinazolines" <i>Khimiko-Farmatsevticheskii Zhurnal</i> (1978) 12(11) 44-48			<input type="checkbox"/>

Examiner Signature		Date Considered	5/11/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[^]Applicant's unique citation designation number (optional). ² Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4810-73194-01
Application Number	10/567,660
Filing Date	February 8, 2006
First Named Inventor	Chamberland
Art Unit	1624
Examiner Name	Tamthom Ngo Truong

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
<i>TNT</i>	<input checked="" type="checkbox"/>	Supplementary European Search Report for Application No. EP 04 76 1630, 2 pages, dated November 11, 2006.
<i>TNT</i>	<input checked="" type="checkbox"/>	Moskalenko, N. Yu, et al., "4-Amino-styrylquinazolines – a new class of antiprotozoal drugs," <i>Database Caplus [Online] Chemical Abstracts Service</i> , XP002404560 retrieved from STN, Database accession no. 1987:32975, 2 pages.
<i>TNT</i>	<input checked="" type="checkbox"/>	Khimiko-Farmatsevticheskii Zhurnal, 20(4), 437-446, Coden: KHFZAN; ISSN: 0023-1134, 1986, XP002917813. (See cite No. C8 on Information Disclosure Statement dated June 20, 2006.).

EXAMINER SIGNATURE:		DATE CONSIDERED:	5/11/07
------------------------	---	---------------------	---------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.